GCNT3 anticorps (C-Term) (APC)
-
- Antigène Voir toutes GCNT3 Anticorps
- GCNT3 (Glucosaminyl (N-Acetyl) Transferase 3, Mucin Type (GCNT3))
-
Épitope
- AA 390-418, C-Term
-
Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp GCNT3 est conjugé à/à la APC
-
Application
- Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS)
- Réactivité croisée
- Humain, Souris
- Réactivité croisée (Details)
- Calculated cross reactivity: Hu Mo
- Attributs du produit
- GCNT3, CT (GCNT3, Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3, C2GnT-mucin type, Core 2/core 4 beta-1,6-N-acetylglucosaminyltransferase) (APC)
- Purification
- Purified by Protein A affinity chromatography.
- Immunogène
- GCNT3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 390-418 amino acids from the C-terminal region of human GCNT3.
- Isotype
- IgG
- Top Product
- Discover our top product GCNT3 Anticorps primaire
-
-
- Indications d'application
- Optimal working conditions should be determined by the investigator.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- Supplied as a liquid in PBS, pH 7.2.
- Stock
- 4 °C
- Stockage commentaire
- 4°C ,Do Not Freeze
-
- Antigène
- GCNT3 (Glucosaminyl (N-Acetyl) Transferase 3, Mucin Type (GCNT3))
- Autre désignation
- GCNT3 (GCNT3 Produits)
- Synonymes
- anticorps C2/4GnT, anticorps C24GNT, anticorps C2GNT2, anticorps C2GNTM, anticorps GNTM, anticorps 2010013H22Rik, anticorps 2210021I22Rik, anticorps 2210401J11Rik, anticorps beta-16-N-acetylglucosaminyltransferase, anticorps dI/C2/C4GnT, anticorps c2/4gnt, anticorps c24gnt, anticorps c2gnt2, anticorps c2gntm, anticorps gntm, anticorps glucosaminyl (N-acetyl) transferase 3, mucin type, anticorps glucosaminyl (N-acetyl) transferase 3, mucin type L homeolog, anticorps GCNT3, anticorps Gcnt3, anticorps gcnt3.L
- NCBI Accession
- NP_004742
- UniProt
- O95395
- Pathways
- Production of Molecular Mediator of Immune Response
-